ERAS-3490 / Erasca - LARVOL DELTA

Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates (GlobeNewswire) - "Key Upcoming Anticipated Milestones:...(i) THUNDERBBOLT-1: Phase 1 trial for ERAS-801 in patients with recurrent glioblastoma multiforme (GBM) - Initial Phase 1 data in recurrent GBM in second half of 2023; (ii) AURORAS-1: Phase 1 trial for ERAS-3490 in patients with KRAS G12Cm NSCLC - Initial Phase 1 data in 2024."

P1 data • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer • KRAS

Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors (GlobeNewswire) - "Erasca...announced the United States Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for ERAS-3490, an orally available small molecule KRAS G12C inhibitor designed to have high central nervous system (CNS) penetration for the treatment of KRAS G12C-mutated solid tumors, including non-small cell lung cancer (NSCLC)."

IND • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Erasca Reports Third Quarter 2022 Financial Results and Business Updates (GlobeNewswire) - "Key Upcoming Milestones: ERAS-3490: IND filing anticipated in the second half of 2022.... Initiation of a Phase 1b dose escalation trial for ERAS-007 in combination with ERAS-601 (Erasca’s first MAPKlamp approach) anticipated in the first half of 2023, HERKULES-3: Initial Phase 1b combination data anticipated in the first half of 2023, FLAGSHP-1: Phase 1/1b trial for ERAS-601 in patients with advanced solid tumors, Initial Phase 1b combination data in triple wildtype (KRAS/NRAS/BRAF wildtype) CRC anticipated in the first half of 2023....HERKULES-2: Phase 1b/2 trial for ERAS-007 in patients with advanced NSCLC, Initial Phase 1b combination data anticipated in 2023."

IND • P1 data • P1/2 data • Trial status • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Erasca Presents Compelling Preclinical Data Supporting Clinical Development of Potentially Best-In-Class Programs ERAS-007, ERAS-601, and ERAS-3490 at 2022 AACR Annual Meeting (GlobeNewswire) - "ERAS-007 demonstrates promising preclinical activity across a wide range of RAS/MAPK pathway-driven CRC models both as a monotherapy and in combination...The ERAS-007 + ERAS-601 MAPKlamp combination achieved superior tumor growth inhibition and regression over either agent alone in KRAS mutant NSCLC, CRC, and PDAC xenografts in vivo....ERAS-3490 shows robust anti-tumor activity and dose-dependent survival benefit in the KRAS G12C NSCLC intracranial model NCI-H1373-luc, a nonclinical model of NSCLC CNS metastasis."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • Thoracic Cancer

Erasca Reports Fourth Quarter 2021 Financial Results and Business Updates - "Erasca, Inc...today reported financial results for the fiscal quarter ended December 31, 2021, and provided business updates....Announced Six Poster Presentations at the 2022 AACR Annual Meeting: In March 2022, Erasca announced six poster presentations, featuring programs with best-in-class potential, including ERK1/2 inhibitor ERAS-007, SHP2 inhibitor ERAS-601, and CNS-penetrant KRAS G12C inhibitor ERAS-3490. Erasca will be hosting an investor webinar on Tuesday, April 12, 2022, highlighting its 2022 AACR presentations and featuring a presentation by key opinion leader Scott Kopetz..."

Clinical

Erasca Reports Fourth Quarter 2021 Financial Results and Business Updates (GlobeNewswire) - “HERKULES-1: Phase 1b/2 trial for ERAS-007/MAPKlamp in patients with advanced solid tumors. Initial Phase 1b monotherapy data expected in second half of 2022. HERKULES-3: Phase 1b/2 trial for ERAS-007 in patients with gastrointestinal (GI) malignancies. Initial Phase 1b combination data expected between the fourth quarter of 2022 and the first half of 2023. FLAGSHP-1: Phase 1/1b trial for ERAS-601 in patients with advanced solid tumors. Initial Phase 1 monotherapy data expected in second half of 2022. Initial Phase 1b combination data in triple wildtype (KRAS/NRAS/BRAF wildtype) CRC expected between the fourth quarter of 2022 and the first half of 2023. ERAS-3490: CNS-penetrant KRAS G12C inhibitor. IND filing expected in second half of 2022”

IND • P1 data • Gastrointestinal Cancer • Oncology • Solid Tumor